OxoLog Entry
The Heart Disease Test We Still Use Was Built in the ’60s. And It Sucks.
2025-05-25
🧠 The Medical System's Favorite Relic
The Framingham Risk Score, created in 1968, is still the go-to tool for predicting heart disease.
It uses:
- Age
- Gender
- Blood pressure
- Smoking
- Total cholesterol
- HDL
That’s it. That’s the gold standard. Still.
It’s like trying to predict a plane crash using only altitude and engine noise.
💣 What Framingham Misses Completely
It doesn’t track:
- Oxidative stress
- Endothelial damage
- Lipid peroxidation
- Mitochondrial dysfunction
- 4-HNE, 9-HODE, MDA — real markers of collapse
Framingham was revolutionary for its time.
But the science has moved on.
Medicine hasn’t.
📉 The Results? Predictive Failure
- 75% of heart attack patients have normal or low LDL
- “Residual risk” remains after statins — because the real threat was never cholesterol
- Oxidative stress begins years before plaque shows up
Framingham measures the passengers.
OXO tracks the explosion.
🔬 Real Biomarkers. Real Risk.
The OXO Collapse Score quantifies what actually drives cardiovascular collapse:
- 4-HNE — binds to mitochondrial proteins, causes endothelial damage
- 9-HODE — linked to atherosclerotic lesions
- MDA — elevated after myocardial infarction
- Pyroglutamate — signal of glutathione depletion
These are the early warning signals that never make it into a lipid panel.
⚙️ Why We're Replacing It
LDL is lagging.
A1C is late.
Blood pressure is reactive.
You need a system that sees the collapse before it breaks you.
Framingham gave us the past.
OXO gives you the forecast.
Doctors should be scared.
This isn’t just about “patients.”
This is about the same 1960s cholesterol calculator they’ll use on their spouse, their kids, their own body —
while ignoring oxidative collapse, endothelial damage, and mitochondrial distress.
The cost of denial isn’t theoretical. It’s personal.
🧠 TL;DR
- The most used heart disease test is from the 1960s
- It doesn’t measure the actual agents of metabolic collapse
- You’ve been playing the wrong game with the wrong scoreboard
The future of diagnostics isn’t built on cholesterol.
It’s built on oxidation.